



FONDAZIONE MICHELANGELO  
avanzamento dello studio e cura dei tumori



FONDAZIONE IRCCS  
ISTITUTO NAZIONALE  
DEI TUMORI

## Fondazione Michelangelo 10<sup>th</sup> Seminar

### Up-date on HER2-directed therapies in early breast cancer

23rd October 2009

14.00-17.00

Fondazione IRCCS Istituto Nazionale dei Tumori  
Via Venezian, 1 – 20133 Milano

## PRELIMINARY AGENDA

Chairman

F. Puglisi (Udine, I)

- |             |   |   |
|-------------|---|---|
| 14.00-14.30 | <b>C.L. Arteaga</b> (Nashville, Tn - USA)     | Mechanisms of resistance and sensitivity to HER2-directed therapies: implication for clinical studies |
| 14.30-15.00 | <b>M. Sliwkowski</b> (S. Francisco, Ca - USA) | New drugs directed against members of the EGF family of receptors                                     |
| 15.00-15.30 | <b>I. Smith</b> (London, UK)                  | Cross talk between the HER2 and the ER receptors: implications for adjuvant treatment                 |
| 15.30-16.00 | <b>E. Perez</b> (Jacksonville, Fl – USA)      | Where we go in the adjuvant treatment with HER2-directed therapies                                    |
| 16.00-16.30 | <b>L. Gianni</b> (Milan, I)                   | Duration of HER2-directed therapies: implications from the updated results of the HERA trial          |
| 16.30-17.00 | <b>Discussion</b>                             |   |

*ECM requested*